Conference Call with Cipla Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Cipla announced Q1FY25 results: Financial Highlights: Income from Operations: Rs 6,694 crore, up by 7% YoY EBITDA: Rs 1,716 crore, up by 14% YoY PAT: Rs 1,178 crore, up by 17% YoY Business Highlights: One-India: India Branded Prescription Business grew at a healthy rate of 10% YoY. Overall One India growth was offset by softness in Trade Generics Business owing to distribution model change. North America: All-time high revenue at USD 250 million up by 13% YoY supported by traction in differentiated portfolio. South Africa: Momentum continues with revenue growth at 19% in local currency terms. Prescription business ranked #1 in the market R&D; investments: stand at Rs 353 crore or 5.3 % of sales, higher by 1% YoY driven by product filings and developmental efforts. Strong net cash: Net cash position of Rs 8,449 crore; Debt primarily includes lease liabilities and working capital requirements. Compliance update: Patalganga and Kurkumbh facilities were classified as ‘VAI’ by USFDA. Umang Vohra MD and Global CEO, Cipla said: I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6% driven by mix and other operational efficiencies. Our One-India business continued on its growth trajectory during the quarter, led by Branded Prescription which grew at 10%. Our concentrated focus and execution in differentiated portfolio have further strengthened the US business which yet again posted all-time high quarterly revenue at USD 250 million. In South Africa, we recorded a solid growth of 19% YoY in local currency terms, led by Private Market. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”. Result PDF